Antimicrobial dosing in critically ill patients with sepsis-induced acute kidney injury

被引:15
作者
Kumar, Anish [1 ]
Singh, Narinder Pal [1 ]
机构
[1] Pushpanjali Crosslay Hosp, Dept Nephrol, Ghaziabad, Uttar Pradesh, India
关键词
Acute kidney injury; antimicrobial agents; critically ill patient; multiple organ dysfunction syndromes; pharmacodynamics; pharmacokinetics; sepsis;
D O I
10.4103/0972-5229.151018
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Severe sepsis often leads to multiple organ dysfunction syndromes (MODS) with acute kidney injury (AKI). AKI affects approximately, 35% of Intensive Care Unit patients, and most of these are due to sepsis. Mortality rate of sepsis-induced AKI is high. Inappropriate use of antimicrobials may be responsible for higher therapeutic failure, mortality rates, costs and toxicity as well as the emergence of resistance. Antimicrobial treatment is particularly difficult due to altered pharmacokinetic profile, dynamic changes in patient's clinical status and, in many cases, need for renal replacement therapy. This article aims to describe the appropriate antimicrobial dosing and reviews the factors contributing to the difficulties in establishing precise guidelines for antimicrobial dosing in sepsis-induced AKI patients. Search strategy: Text material was collected by systematic search in PubMed, Google (1978-2013) for original articles.
引用
收藏
页码:99 / 108
页数:10
相关论文
共 54 条
[1]   Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion [J].
Adembri, Chiara ;
Fallani, Stefania ;
Cassetta, Maria Iris ;
Arrigucci, Silvia ;
Ottaviano, Alessandra ;
Pecile, Patrizia ;
Mazzei, Teresita ;
De Gaudio, Raffaele ;
Novelli, Andrea .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2008, 31 (02) :122-129
[2]   Cefazolin dosing protocol for patients receiving long-term hemodialysis [J].
Ahern, JW ;
Possidente, CJ ;
Hood, V ;
Alston, WK .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2003, 60 (02) :178-181
[3]   In vivo pharmacodynamics of a new oxazolidinone (linezolid) [J].
Andes, D ;
van Ogtrop, ML ;
Peng, J ;
Craig, WA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (11) :3484-3489
[4]   Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care [J].
Angus, DC ;
Linde-Zwirble, WT ;
Lidicker, J ;
Clermont, G ;
Carcillo, J ;
Pinsky, MR .
CRITICAL CARE MEDICINE, 2001, 29 (07) :1303-1310
[5]  
Aronoff GR, 2007, DRUG PRESCRIBING REN, P97
[6]   Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg [J].
Bergner, R ;
Hoffmann, M ;
Riedel, KD ;
Mikus, G ;
Henrich, DM ;
Haefeli, WE ;
Uppenkamp, M ;
Walter-Sack, I .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (04) :1019-1023
[7]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[8]   Principles of antibacterial dosing in continuous renal replacement therapy [J].
Choi, Gordon ;
Gomersall, Charles D. ;
Tian, Qi ;
Joynt, Gavin M. ;
Freebairn, Ross ;
Lipman, Jeffrey .
CRITICAL CARE MEDICINE, 2009, 37 (07) :2268-2282
[9]   Does the dose matter? [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 2001, 33 :S233-S237
[10]   Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10